1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

English Funding Setback For Novartis’s Mayzent

 
• By Neena Brizmohun

Novartis says that while the comparators used in the evidence it submitted to NICE were the right ones, it will work to address the health technology assessment body’s outstanding data requirements to secure access to its treatment for secondary progressive multiple sclerosis.

stethoscope and digital tablet with MULTIPLE SCLEROSIS word on it screen. healthcare and medical concept
There have been few, if any, treatments for SPMS • Source: Shutterstock

NICE has issued a draft guidance rejecting Novartis’s Mayzent (siponimod) for treating secondary progressive multiple sclerosis, saying that the drug, which is Europe’s first oral treatment for SPMS, should not be used on England’s National Health Service.

While clinical trials have shown that Mayzent can slow the worsening of disability in SPMS, more detailed evidence and analysis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 
• By Francesca Bruce

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

 
• By Neena Brizmohun

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

More from Market Access

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 
• By Eliza Slawther

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.